| Thomas Eugene Chambers Sr, DO | |
|
1800 Quiet Forest Trl, Chuluota, FL 32766-9176 | |
| (407) 399-7014 | |
| Not Available |
| Full Name | Thomas Eugene Chambers Sr |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Location | 1800 Quiet Forest Trl, Chuluota, Florida |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972973485 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | OS 1530 (Florida) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Thomas Eugene Chambers Sr, DO 1800 Quiet Forest Trl, Chuluota, FL 32766-9176 Ph: (407) 399-7014 | Thomas Eugene Chambers Sr, DO 1800 Quiet Forest Trl, Chuluota, FL 32766-9176 Ph: (407) 399-7014 |
News Archive
Moraga Biotechnology Corporation, an adult stem cell company based in Culver City, California, announces the publication of its blood-derived Blastomere-Like Stem Cells (BLSCs) patent with the European Patent Office.
Biophotonics, or photomedicine, is a relatively unknown discipline, though it has existed for years now. You may have even benefited from it without realizing it. Some of the greatest advances of this field can be found in applications for the areas of oncology, dermatology, ophthalmology, surgery and cardiology.
Cleveland Clinic researcher Jun Qin, Ph.D., has been named a Fellow of the American Association for the Advancement of Science (AAAS). As part of the Molecular Cardiology Department in the Lerner Research Institute, Qin was elected as an AAAS Fellow for exemplary contributions to the field of cell signaling.
On 21 February Bill Gates met with Dr. Carlos Martin of the University of Zaragoza and members of his team in Madrid, Spain. The scientists are working on the development of MTBVAC, a new vaccine against tuberculosis (TB). Gates showed great interest in the scientific background of MTBVAC, the most advanced vaccine based on attenuation of Mycobacterium tuberculosis.
A first-ever, long-term study of patients who underwent robot-assisted surgery to remove their cancerous prostates found that nearly 87 percent of them had no recurrence of the disease after five years.
› Verified 6 days ago